Species distribution and drug susceptibility of candida in clinical isolates from a tertiary care centre at Indore

Indian Journal of Medical Microbiology

Volumn 32, Issue 1, 2014, Pages 44-48

  Pahwa, N ^a   Kumar, R ^b   Nirkhiwale, S ^a   Bandi, A ^a  

^a Greater Kailash Hospital   (India)

^b SRI AUROBINDO INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antifungal susceptibility; Candida; infection

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CHILD; CLAVISPORA LUSITANIAE; CYBERLINDNERA JADINII; FEMALE; HUMAN; INTENSIVE CARE UNIT; KLUYVEROMYCES LACTIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PICHIA GUILLIERMONDII; PRESCHOOL CHILD; SCHOOL CHILD; SPECIES DISTRIBUTION; TERTIARY CARE CENTER; WICKERHAMOMYCES ANOMALUS; YARROWIA LIPOLYTICA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84892769212     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.124300     Document Type: Article

References (20)

1. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011;39:665-70.
2. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med 2012;40:813-22.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7.
4. Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011;49:3300-8.
5. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron M, et al. Msg-01: A multicenter, randomized, double-blind, placebo controlled trial of caspofungin (cas) prophylaxis vs placebo followed by pre-emptive therapy for invasive candidiasis (ic) in high-risk adults in the critical care setting. Preliminary results. SHEA Annual Scientific Meeting. Dallas, Texas, United States; 2011.
6. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006;43:25-31.
7. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136:1237-48.
8. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID Diagnostic and Management Guidelines of Candida Diseases 2012: Diagnostic Procedures. Clin Microbiol Infect 2012;18 Suppl 7:9-18.
9. Shao LC, Sheng CQ, Zhang WN. Recent advances in the study of antifungal lead compounds with new chemical scaffolds. Yao Xue Xue Bao 2007;42:1129-36.
10. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
11. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007;45:3522-8.
12. Murray MP, Zinchuk R, Larone DH. CHROMagar Candida as the sole primary medium for I solation of yeasts and as a source medium for the rapid-assimilation-of-trehalose test. J Clin Microbiol 2005;43:1210-2.
13. Baillie GS, Douglas LJ. Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B. Antimicrob Agents Chemother 1998;42:2146-9.
14. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008;12:204.
15. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: A 10-year study. J Med Microbiol 2007;56:255-9.
16. Jain N, Mathur P, Misra MC, Behera B, Xess I, Sharma SP. Rapid identification of yeast isolates from clinical specimens in critically ill trauma ICU patients. J Lab Physicians 2012;4:30-4.
17. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida tropicalis: Its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol 2010;59:873-80.
18. Mathews MS, Samuel PR, Suresh M. Emergence of Candida tropicalis as the major cause of fungaemia in India. Mycoses 2001;44:278-80.
19. Kothari A, Sagar V. Epidemiology of candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 2008;27:171-2.
20. Adhikary R, Joshi S. Species distribution and antifungal susceptibility of candidemia at a multi super specialty centre in Southern India. Indian J Med Microbiol 2011;29:309-11.